Allianz SE Purchases New Position in Humana Inc. (NYSE:HUM)

Allianz SE bought a new position in Humana Inc. (NYSE:HUM - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 13,960 shares of the insurance provider's stock, valued at approximately $3,549,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. FPC Investment Advisory Inc. bought a new stake in shares of Humana during the fourth quarter worth about $27,000. Centricity Wealth Management LLC acquired a new position in Humana during the 4th quarter valued at about $30,000. LFA Lugano Financial Advisors SA increased its holdings in Humana by 56.3% during the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock worth $32,000 after purchasing an additional 45 shares in the last quarter. OFI Invest Asset Management purchased a new stake in shares of Humana in the fourth quarter worth approximately $33,000. Finally, Atwood & Palmer Inc. lifted its holdings in shares of Humana by 64.5% in the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider's stock valued at $39,000 after purchasing an additional 60 shares in the last quarter. Institutional investors own 92.38% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on HUM shares. Truist Financial increased their price target on Humana from $260.00 to $290.00 and gave the company a "hold" rating in a research report on Monday, January 6th. Barclays raised their price target on shares of Humana from $255.00 to $270.00 and gave the company an "equal weight" rating in a research report on Thursday, February 13th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $290.00 price objective on shares of Humana in a research report on Wednesday, February 12th. StockNews.com lowered shares of Humana from a "buy" rating to a "hold" rating in a research note on Tuesday, March 18th. Finally, Piper Sandler boosted their target price on Humana from $270.00 to $288.00 and gave the stock a "neutral" rating in a research note on Wednesday, January 15th. Eighteen investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, Humana has a consensus rating of "Hold" and an average target price of $285.68.

Remove Ads

Humana Price Performance

Shares of HUM traded down $0.05 during trading hours on Tuesday, reaching $264.55. 927,232 shares of the stock traded hands, compared to its average volume of 1,753,344. The company has a market cap of $31.93 billion, a P/E ratio of 26.59, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The company's 50-day moving average price is $269.77 and its two-hundred day moving average price is $273.07. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $406.46.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. On average, analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.34%. The ex-dividend date is Friday, March 28th. Humana's dividend payout ratio (DPR) is presently 35.58%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.